Comparative Pharmacology
Head-to-head clinical analysis: CEFOTAXIME AND DEXTROSE 3 9 IN PLASTIC CONTAINER versus CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTAXIME AND DEXTROSE 3 9 IN PLASTIC CONTAINER versus CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER.
CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER vs CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefotaxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
Cefotetan is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), resulting in cell lysis and death.
1-2 g IV every 4-6 hours; maximum 12 g/day.
1 to 2 g intravenously every 12 hours for 5 to 10 days. For severe infections, 2 g intravenously every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 0.8-1.4 hours in adults with normal renal function; prolonged to 2.5-15 hours in renal impairment; clinical context: dosing interval adjustment required for CrCl <20 mL/min
Terminal elimination half-life 3-4 hours in normal renal function; prolonged in renal impairment (e.g., up to 13 hours in severe renal failure).
Primarily renal (80-90% unchanged within 24 hours); biliary/fecal elimination accounts for <10%
Primarily renal (unchanged drug) ~88%; minor biliary/fecal ~6-9%.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic